Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013

Lydia Turner, Stefan P. Kruszewski, George Caleb Alexander

Research output: Contribution to journalArticle

Abstract

Background and Objectives Despite buprenorphine's promise as a novel therapy for opioid dependence, little is known about its clinical adoption. We characterized trends in ambulatory use of buprenorphine in the United States. Methods Cross-sectional, descriptive analyses of buprenorphine utilization from 2003 to 2013 using the IMS Health National Disease and Therapeutic Index, a nationally representative audit of ambulatory care. The primary unit of analysis was an office visit where buprenorphine was used for opioid dependence (treatment visit). Results Between 2003 and 2013, there was significant uptake of buprenorphine in ambulatory treatment visits, from 0.16 million [M] (95% confidence interval [CI] 0.10-0.20) visits in 2003 to 2.1M (CI 1.9-2.3M) treatment visits during 2013. Approximately 90% involved the use of brand name combination buprenorphine/naloxone (Suboxone), although this percentage decreased modestly to 80% by the last quarter of 2013. Buprenorphine prescribing increased among all specialties, but the proportion accounted for by primary care physicians increased significantly from 6.0% in 2003 to 63.5% in 2013 and decreased among psychiatrists from 92.2% to 32.8% over the same time period. Conclusions The use of buprenorphine products to treat opioid dependence has increased significantly in the past 10 years and has shifted to greater use by primary care physicians, indicating a rapidly changing face of opioid maintenance therapy in the United States. (Am J Addict 2015;24:24-29)

Original languageEnglish (US)
Pages (from-to)24-29
Number of pages6
JournalAmerican Journal on Addictions
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Physicians' Offices
Buprenorphine
Opioid Analgesics
Primary Care Physicians
Therapeutics
Confidence Intervals
Office Visits
Ambulatory Care
Names
Psychiatry
Cross-Sectional Studies
Health

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013. / Turner, Lydia; Kruszewski, Stefan P.; Alexander, George Caleb.

In: American Journal on Addictions, Vol. 24, No. 1, 01.01.2015, p. 24-29.

Research output: Contribution to journalArticle

@article{d2feb95de5764db89536c10b9647dd49,
title = "Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013",
abstract = "Background and Objectives Despite buprenorphine's promise as a novel therapy for opioid dependence, little is known about its clinical adoption. We characterized trends in ambulatory use of buprenorphine in the United States. Methods Cross-sectional, descriptive analyses of buprenorphine utilization from 2003 to 2013 using the IMS Health National Disease and Therapeutic Index, a nationally representative audit of ambulatory care. The primary unit of analysis was an office visit where buprenorphine was used for opioid dependence (treatment visit). Results Between 2003 and 2013, there was significant uptake of buprenorphine in ambulatory treatment visits, from 0.16 million [M] (95{\%} confidence interval [CI] 0.10-0.20) visits in 2003 to 2.1M (CI 1.9-2.3M) treatment visits during 2013. Approximately 90{\%} involved the use of brand name combination buprenorphine/naloxone (Suboxone), although this percentage decreased modestly to 80{\%} by the last quarter of 2013. Buprenorphine prescribing increased among all specialties, but the proportion accounted for by primary care physicians increased significantly from 6.0{\%} in 2003 to 63.5{\%} in 2013 and decreased among psychiatrists from 92.2{\%} to 32.8{\%} over the same time period. Conclusions The use of buprenorphine products to treat opioid dependence has increased significantly in the past 10 years and has shifted to greater use by primary care physicians, indicating a rapidly changing face of opioid maintenance therapy in the United States. (Am J Addict 2015;24:24-29)",
author = "Lydia Turner and Kruszewski, {Stefan P.} and Alexander, {George Caleb}",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/ajad.12174",
language = "English (US)",
volume = "24",
pages = "24--29",
journal = "American Journal on Addictions",
issn = "1055-0496",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013

AU - Turner, Lydia

AU - Kruszewski, Stefan P.

AU - Alexander, George Caleb

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background and Objectives Despite buprenorphine's promise as a novel therapy for opioid dependence, little is known about its clinical adoption. We characterized trends in ambulatory use of buprenorphine in the United States. Methods Cross-sectional, descriptive analyses of buprenorphine utilization from 2003 to 2013 using the IMS Health National Disease and Therapeutic Index, a nationally representative audit of ambulatory care. The primary unit of analysis was an office visit where buprenorphine was used for opioid dependence (treatment visit). Results Between 2003 and 2013, there was significant uptake of buprenorphine in ambulatory treatment visits, from 0.16 million [M] (95% confidence interval [CI] 0.10-0.20) visits in 2003 to 2.1M (CI 1.9-2.3M) treatment visits during 2013. Approximately 90% involved the use of brand name combination buprenorphine/naloxone (Suboxone), although this percentage decreased modestly to 80% by the last quarter of 2013. Buprenorphine prescribing increased among all specialties, but the proportion accounted for by primary care physicians increased significantly from 6.0% in 2003 to 63.5% in 2013 and decreased among psychiatrists from 92.2% to 32.8% over the same time period. Conclusions The use of buprenorphine products to treat opioid dependence has increased significantly in the past 10 years and has shifted to greater use by primary care physicians, indicating a rapidly changing face of opioid maintenance therapy in the United States. (Am J Addict 2015;24:24-29)

AB - Background and Objectives Despite buprenorphine's promise as a novel therapy for opioid dependence, little is known about its clinical adoption. We characterized trends in ambulatory use of buprenorphine in the United States. Methods Cross-sectional, descriptive analyses of buprenorphine utilization from 2003 to 2013 using the IMS Health National Disease and Therapeutic Index, a nationally representative audit of ambulatory care. The primary unit of analysis was an office visit where buprenorphine was used for opioid dependence (treatment visit). Results Between 2003 and 2013, there was significant uptake of buprenorphine in ambulatory treatment visits, from 0.16 million [M] (95% confidence interval [CI] 0.10-0.20) visits in 2003 to 2.1M (CI 1.9-2.3M) treatment visits during 2013. Approximately 90% involved the use of brand name combination buprenorphine/naloxone (Suboxone), although this percentage decreased modestly to 80% by the last quarter of 2013. Buprenorphine prescribing increased among all specialties, but the proportion accounted for by primary care physicians increased significantly from 6.0% in 2003 to 63.5% in 2013 and decreased among psychiatrists from 92.2% to 32.8% over the same time period. Conclusions The use of buprenorphine products to treat opioid dependence has increased significantly in the past 10 years and has shifted to greater use by primary care physicians, indicating a rapidly changing face of opioid maintenance therapy in the United States. (Am J Addict 2015;24:24-29)

UR - http://www.scopus.com/inward/record.url?scp=84961373718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961373718&partnerID=8YFLogxK

U2 - 10.1111/ajad.12174

DO - 10.1111/ajad.12174

M3 - Article

VL - 24

SP - 24

EP - 29

JO - American Journal on Addictions

JF - American Journal on Addictions

SN - 1055-0496

IS - 1

ER -